MPL proto-oncogene, thrombopoietin receptor
Dernière mise à jour 14 avr. 2023
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Version audio
- Ajouter aux sources préférées sur Google
La MPL gene provides instructions for making the thrombopoietin receptor protein, which promotes the growth and division (proliferation) of cells. This receptor is especially important for the proliferation of certain blood cells called megakaryocytes, which produce platelets, the cells involved in blood clotting. Research suggests that the thrombopoietin receptor may also play a role in the maintenance of hematopoietic stem cells, which are stem cells located within the bone marrow that have the potential to develop into red blood cells, white blood cells, and platelets.
Normal function
La MPL gene provides instructions for making the thrombopoietin receptor protein, which promotes the growth and division (proliferation) of cells. This receptor is especially important for the proliferation of certain blood cells called megakaryocytes, which produce platelets, the cells involved in blood clotting. Research suggests that the thrombopoietin receptor may also play a role in the maintenance of hematopoietic stem cells, which are stem cells located within the bone marrow that have the potential to develop into red blood cells, white blood cells, and platelets.
The thrombopoietin receptor is turned on (activated) when a protein called thrombopoietin attaches (binds) to it. The activated thrombopoietin receptor stimulates a signaling pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the cell's nucleus and is important for controlling the production of blood cells.
Conditions referring to this gene or chromosome
Other names
C-MPL
CD110
MPLV
myeloproliferative leukemia protein
myeloproliferative leukemia virus oncogene
proto-oncogene c-Mpl
thrombopoietin receptor
thrombopoietin receptor precursor
TPO-R
TPOR
TPOR_HUMAN
Related patient information and medicines
Patient information leaflet
Myélofibrose
Qu'est-ce que myelofibrosis. Myélofibrose belongs to a group of diseases called myeloproliferative disorders. Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. This leads to reduced levels of: Red blood cells (erythrocytes). Already having another blood disorder, such as essential thro... Having.
Patient information leaflet
Purpura thrombocytopénique immunologique
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder. In autoimmune disorders your body makes proteins called antibodies which damag... The National Institute for Health and Care Excellence (NICE) has looked at the evidence for this medicine and advised that it can be used when other medicines have been tried. Specifically, these other.
Patient information leaflet
Cancer du sein
Si cancer du sein is diagnosed at an early stage, less un traitement may be needed and it is more likely to be effective. In general, the more advanced the cancer (the more it has grown and spread), the less chance that treatment will be curative. However, treatments are improving all the time and they can often slow the progress of the cancer. Breast.
Patient information leaflet
Puis-je prendre Alogliptin et Rybelsus ensemble ?
Prendre alogliptin and Rybelsus (semaglutide) together can significantly increase the risk of your votre glycémie dropping too low (hypoglycaemia). Alogliptin (a DPP-4 inhibitor) prevents the breakdown of natural hormones cela lower blood sugar, while Rybelsus (a GLP-1 receptor agonist) mimics those same hormones. ...ibitor (alogliptin) when starting.
Patient information leaflet
Pontage aortocoronarien
C oronary artery bypass grafting (CABG) is a type of heart surgery to treat coronary artery disease. The standard surgery requires open heart surgery and stopping of the heart temporarily. Coronary artery bypass grafting, called CABG for short (pronounced 'cabbage'), is a heart operation. It is also called coronary artery bypass surgery. A CABG is.
Patient information leaflet
Hypercholestérolémie familiale
Familial hypercholesterolaemia (FH) est called familial because it runs in the family (the other word for this is 'inherited'). Hypercholesterolaemia means cholesterol levels in your blood are too high. Too much cholesterol in your blood causes cholesterol deposits in your arteries and so an increased risk of early heart disease (coronary heart.
Lectures complémentaires et références
- MPL proto-oncogene, thrombopoietin receptor; MedlinePlus, National Library of Medicine.
- Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socie G, Bordessoule D, Le Bousse-Kerdiles MC, Vainchenker W, Giraudier S. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008 Aug;22(8):1557-66. doi: 10.1038/leu.2008.137. Epub 2008 Jun 5.
- Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A, Ishida T, Nitta M, Ueda R. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009 Oct 8;114(15):3325-8. doi: 10.1182/blood-2008-04-149047. Epub 2009 May 29.
- Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat. 2006 Mar;27(3):296. doi: 10.1002/humu.9415.
- Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270.
- Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29.
Historique de l'article
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
14 avr. 2023 | Dernière version
1 Sept 2014 | Publié à l'origine
Participez à la conversation
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets de santé.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.